How much revenue does Mabwell (Shanghai) Bioscience make?

Mabwell (Shanghai) Bioscience reported 199.78 million CNY in revenue for fiscal year 2024, up 56.3% from 127.84 million CNY in fiscal year 2023. In Q2 2025 revenue was 56.38 million CNY.

Where does Mabwell (Shanghai) Bioscience make most of its revenue?

Mainland China: 88% of revenue by region in fiscal year 2025, followed by Other Regions (12%).

What companies are similar to Mabwell (Shanghai) Bioscience?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Beijing Aosaikang Pharmaceutical Co., Ltd. (002755.SZ), Yifan Pharmaceutical Co., Ltd. (002019.SZ), Shanghai Haixin Group Co., Ltd. (600851.SS), Hunan Jingfeng Pharmaceutical Co.,Ltd. (000908.SZ).

Mabwell (Shanghai) Bioscience Co., Ltd. (688062.SS) Stock

About Mabwell (Shanghai) Bioscience Co., Ltd.

Mabwell (Shanghai) Bioscience Co., Ltd., a biopharmaceutical company, engages in the research and development, manufacture, and commercialization of biological products for oncology, immunology, bone disorders, ophthalmology, hematology, and infectious diseases in China and internationally. The company offers MAIWEIJIAN for the treatment of giant cell tumor of bone; MALISHU for the treatment of po...

At a glance

Mabwell (Shanghai) Bioscience reported revenue of 199.78 million CNY for fiscal year 2024, up 56.3% from fiscal year 2023, and net income of -1.04 billion CNY. In Q2 2025 (the quarter ended June 30, 2025) revenue was 56.38 million CNY, up 17.5% from a year before. Mainland China was its largest region in fiscal year 2025, with 88% of revenue.

Figures from company filings; latest fiscal year ended December 31, 2024.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.